Dimerix Limited advised that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin angiotensin system (RAS) modulation study domain in patients with COVID-19 pneumonia, which incorporates DMX-200. Of those 167 subjects enrolled across 43 clinical sites, 106 have been recruited in sites across the UK, 60 in the Netherlands and 1 in Italy and represents an ~7-fold increase over the past 3-months. DMX-200 has regulatory approval in both the UK and the Netherlands and is available at sites for administration to patients randomised to the DMX-200 treatment arm. Even as vaccination rates increase, it is anticipated that a significant proportion of the population will still be susceptible to COVID-19 because they are either resistant to the vaccine, cannot be vaccinated or choose not to be vaccinated. Therefore, it is still likely that many patients will get infected and will end up with COVID respiratory complications and potentially long-COVID (symptoms that extend long beyond recovery from the virus). As such, there remains a great need for treatments for patients with COVID. According to the World Health Organisation (WHO), 195 million COVID cases have been reported to date, including 3.9 million (+10% on prior week) in the past 7 days. This coincides with an increase in the number of deaths globally, with 70,000 reported in the last 7 days (+21% on prior week) and over 4.2 million in total. Europe is currently bracing for a fourth wave anticipated as the territory enters Autumn. In the REMAP-CAP approved ACE2 RAS study domain, participants who meet platform entry criteria will be randomised to receive one RAS blockade treatment arm or a control: ARB in combination with DMX-200, Angiotensin receptor blocker (ARB), Angiotensin converting enzyme (ACE) inhibitor, No RAS inhibitor (no placebo). The feasibility/Phase 3 study is a multi-centre, randomised, standard of care vs multi-active comparators platform study in patients with COVID-19. The overarching REMAP-CAP study incorporating DMX-200 is funded by the European Union through the H2020 Project called "Rapid European COVID-19 Emergency Research response," which uses the acronym "RECOVER". Should current recruitment rates continue, the study is expected to be fully enrolled Fourth Quarter CY 2021, with preliminary data available soon thereafter. DMX-200 is included in the investigator-led feasibility/Phase 3 study in patients with COVID-19 pneumonia, driven by a consortium of global trialists, clinicians and experts through the study sponsor, REMAP-CAP. The study, endorsed by the World Health Organization (WHO), has initiated a master protocol across over 300 clinical sites across eight global regions. REMAP-CAP has investigated 48 active treatments for COVID-19, mostly repurposed and novel medicines, including for registration purposes. The study has now recruited over 7,000 patients with suspected or proven COVID-19 overall. Two Phase 3 Clinical Studies in Respiratory Complications Associated with COVID-19 Dimerix lead drug candidate, DMX-200, is part of two different investigator-led Phase 3 studies in COVID-19 patients with respiratory complications. For one of these studies, Dimerix was awarded $1 million from MTPConnect's Biomedical Translation Bridge (BTB) program provided by the Australian Government's Medical Research Future Fund, with support from UniQuest. Dimerix proactively supports both studies driven by the REMAP-CAP and CLARITY 2.0 teams in providing them information for the regulatory submissions and in supplying DMX-200 to the study sites. Dimerix looks forward to reporting on progress and as key milestones are met. Importantly, if DMX-200 does show benefit in patients with COVID-19, it may also show benefit in respiratory complications associated with other infections, such as pneumonia and influenza. Thus, this provides an opportunity that could extend well beyond the impact of COVID-19. Dimerix continues to progress the Phase 3 pivotal program in FSGS, a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage kidney failure, as well as assess the next study design in diabetic kidney disease patients and finally advance the COPD program towards the clinical stage of development.